Oral cavity immune response in pancreatic ductal adenocarcinoma (PDAC)

被引：0
|
作者：
Marquez, J. P. [1 ]
Lucero-Diaz, P. A. [1 ]
Matute-Briseno, J. A. [1 ]
Rosas-Delgado, M. O. [1 ]
Camacho-Hernandez, A. [1 ]
Cortez-Vargas, Y. [1 ]
Nava-Sanchez, I. [1 ]
Montano, G. T. [1 ]
Montijo-Fernandez, L. N. [1 ]
Perez-Astorga, M. A. [1 ]
机构：
[1] CICS, Clin ImmunoOncol & Relapse Prevent Clin, Obregon, Mexico
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
140P
引用
收藏
页码：44 / 44
页数：1
相关论文
共 50 条
  • [1] Targeting Pancreatic Ductal Adenocarcinoma (PDAC)
    Parrasia, Sofia
    Zoratti, Mario
    Szabo, Ildiko
    Biasutto, Lucia
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2021, 55 (01) : 61 - 90
  • [2] Prediction of response to pelareorep plus pembrolizumab in pancreatic ductal adenocarcinoma (PDAC).
    Fountzilas, Christos
    Wilkinson, Grey A.
    Eng, Kevin H.
    Fields, Paul
    Arora, Sukeshi Patel
    Kalinski, Pawel
    Raber, Patrick
    Nuovo, Gerard
    Coffey, Matthew C.
    Mahalingam, Devalingam
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC)
    Le, Kai
    Wang, Jia
    Zhang, Tao
    Guo, Yifan
    Chang, Hong
    Wang, Siyuan
    Zhu, Bin
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2020, 17 (04): : 422 - 427
  • [4] Pancreatic ductal adenocarcinoma (PDAC) early detection
    Hinestrosa, Juan P.
    Dhani, Harmeet
    Schroeder, Gregor
    Lewis, Jean M.
    Balcer, Heath I.
    Kurzrock, Razelle
    Keith, Dove
    Sears, Rosalie
    Billings, Paul
    CANCER RESEARCH, 2023, 83 (07)
  • [5] Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC)
    Chandana, Sreenivasa
    Babiker, Hani M.
    Mahadevan, Daruka
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (02) : 161 - 177
  • [6] Evaluation of systemic inflammatory response (SIR) markers in pancreatic ductal adenocarcinoma (PDAC)
    Markus, M.
    Kasper, S.
    Noureddine, R.
    Abramczyk, M.
    Paul, A.
    Gerken, G.
    Schmid, K. W.
    Markus, P.
    Schumacher, B.
    Meiler, J.
    Wiesweg, M.
    Kaiser, G.
    Dechene, A.
    Trarbach, T.
    Schuler, M.
    Abendroth, A.
    Oncology Research and Treatment, 2015, 38 : 4 - 5
  • [7] The Effects of Treatment on Peripheral Blood Immune Cell Profile in Pancreatic Ductal Adenocarcinoma (PDAC)
    Tulyte, Skaiste
    Characiejus, Dainius
    Matuzeviciene, Reda
    Janiulioniene, Ausra
    Radzevicius, Mantas
    Zvirblis, Tadas
    Sileikis, Audrius
    ANTICANCER RESEARCH, 2022, 42 (06) : 3067 - 3073
  • [8] Prognostic Metabolic Signatures in Pancreatic Ductal Adenocarcinoma (PDAC).
    Karasinska, Joanna
    Kalloger, Steve
    Wong, Hui-Li
    Renouf, Daniel
    Schaeffer, David
    LABORATORY INVESTIGATION, 2018, 98 : 680 - 680
  • [9] The Beginning of the End of Nihilism in Pancreatic Ductal Adenocarcinoma (PDAC)?
    Johnson, K. M.
    Firpo, M. A.
    Boucher, K. M.
    Scaife, C. L.
    Mulvihill, S. J.
    PANCREAS, 2013, 42 (08) : 1357 - 1357
  • [10] Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC)
    Babiker, Hani M.
    Karass, Michael
    Recio-Boiles, Alejandro
    Chandana, Sreenivasa R.
    McBride, Ali
    Mahadevan, Daruka
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (07) : 583 - 592
12345